Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. Headquartered in Cambridge, Massachusetts, the company is backed by F-Prime Capital Partners and ARCH Venture Partners, two of the world's leading biotech venture capital firms.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/14/18 | $87,000,000 | Series A |
ARCH Venture Partners F-Prime Capital Partners  | undisclosed |
| 03/06/19 | $135,000,000 | Series B |
Altitude Life Science Ventures ARCH Venture Partners Cormorant Asset Management Eight Roads F-Prime Capital Partners Omega Funds Redmile Group | undisclosed |
